-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Equities Analysts Set Expectations for Ironwood Pharmaceuticals, Inc.'s Q4 2022 Earnings (NASDAQ:IRWD)
Equities Analysts Set Expectations for Ironwood Pharmaceuticals, Inc.'s Q4 2022 Earnings (NASDAQ:IRWD)
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) – Analysts at Capital One Financial lowered their Q4 2022 earnings estimates for Ironwood Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 25th. Capital One Financial analyst T. Chiang now expects that the biotechnology company will earn $0.25 per share for the quarter, down from their previous forecast of $0.29. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $1.00 per share.
Get Ironwood Pharmaceuticals alerts:Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $108.64 million for the quarter, compared to the consensus estimate of $111.51 million. Ironwood Pharmaceuticals had a return on equity of 30.24% and a net margin of 39.85%.
Separately, StockNews.com cut shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, December 17th.Ironwood Pharmaceuticals Stock Up 1.6 %
NASDAQ IRWD opened at $11.49 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 25.78 and a current ratio of 25.78. The firm has a 50-day simple moving average of $11.88 and a 200 day simple moving average of $11.37. Ironwood Pharmaceuticals has a twelve month low of $9.73 and a twelve month high of $12.95. The stock has a market cap of $1.76 billion, a PE ratio of 12.09 and a beta of 0.96.
Institutional Trading of Ironwood Pharmaceuticals
Several hedge funds have recently modified their holdings of the company. Natixis Advisors L.P. acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth approximately $340,000. Ritholtz Wealth Management increased its holdings in shares of Ironwood Pharmaceuticals by 46.8% in the fourth quarter. Ritholtz Wealth Management now owns 71,164 shares of the biotechnology company's stock valued at $882,000 after purchasing an additional 22,692 shares in the last quarter. Maryland State Retirement & Pension System acquired a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at approximately $683,000. Ronald Blue Trust Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 18,584.6% in the fourth quarter. Ronald Blue Trust Inc. now owns 4,858 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 4,832 shares in the last quarter. Finally, MQS Management LLC increased its holdings in shares of Ironwood Pharmaceuticals by 77.5% in the third quarter. MQS Management LLC now owns 20,729 shares of the biotechnology company's stock valued at $215,000 after purchasing an additional 9,048 shares in the last quarter.
Insiders Place Their Bets
In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 110,962 shares of the firm's stock in a transaction dated Thursday, January 5th. The shares were sold at an average price of $12.07, for a total transaction of $1,339,311.34. Following the completion of the transaction, the chief executive officer now owns 712,440 shares in the company, valued at $8,599,150.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 13.10% of the company's stock.
Ironwood Pharmaceuticals Company Profile
(Get Rating)
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.
Featured Stories
- Get a free copy of the StockNews.com research report on Ironwood Pharmaceuticals (IRWD)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Ironwood PharmPharmticals,Inc.(纳斯达克代码:IRWD-GET Rating)-第一资本金融的分析师在1月25日星期三发布给客户和投资者的一份研究报告中下调了他们对Ironwood制药2022年第四季度的收益预期。Capital One Financial分析师T.Chiang现在预计,这家生物技术公司本季度每股收益将为0.25美元,低于此前预测的0.29美元。对Ironwood PharmPharmticals目前全年收益的普遍估计为每股1.00美元。
到达铁木制药警报:铁木制药(纳斯达克:IRWD-GET评级)最近一次发布季度收益报告是在11月3日星期四。这家生物技术公司公布本季度每股收益(EPS)为0.28美元,比普遍预期的0.27美元高出0.01美元。该公司本季度营收为1.0864亿美元,而市场普遍预期为1.1151亿美元。Ironwood PharmPharmticals的股本回报率为30.24%,净利润率为39.85%。
另外,在12月17日星期六的一份研究报告中,StockNews.com将Ironwood PharmPharmticals的股票评级从“强势买入”下调至“买入”。铁木制药类股上涨1.6%
纳斯达克IRWD周五开盘报11.49美元。该公司的负债权益比率为0.67,速动比率为25.78,流动比率为25.78。该公司的50日简单移动均线切入位为11.88美元,200日简单移动均线切入位为11.37美元。Ironwood PharmPharmticals的12个月低点为9.73美元,12个月高位为12.95美元。该股市值为17.6亿美元,市盈率为12.09倍,贝塔系数为0.96。
铁木制药的制度性交易
几家对冲基金最近调整了对该公司的持股。Natixis Advisors L.P.在第四季度收购了Ironwood PharmPharmticals价值约34万美元的新股份。Ritholtz Wealth Management在第四季度增持了46.8%的Ironwood PharmPharmticals股票。Ritholtz Wealth Management现在持有这家生物技术公司71,164股,价值882,000美元,上个季度又购买了22,692股。马里兰州退休和养老金系统在第四季度收购了Ironwood制药公司的新股份,价值约68.3万美元。Ronald Blue Trust Inc.在第四季度增持了18,584.6%的Ironwood PharmPharmticals股票。罗纳德·布鲁信托公司(Ronald Blue Trust Inc.)现在持有这家生物技术公司4,858股股票,价值5万美元,该公司在上个季度又购买了4,832股。最后,MQS Management LLC在第三季度增持了77.5%的Ironwood PharmPharmticals股票。MQS Management LLC现在持有这家生物技术公司20,729股股票,价值21.5万美元,上个季度又购买了9,048股。
内部人士下注
在Ironwood PharmPharmticals的其他消息中,首席执行官托马斯·A·麦考特在日期为1月5日星期四的交易中出售了110,962股公司股票。这些股票的平均价格为12.07美元,总成交额为1,339,311.34美元。交易完成后,首席执行官现在拥有该公司712,440股,价值8,599,150.80美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过美国证券交易委员会网站。公司内部人士持有该公司13.10%的股份。
铁木制药公司简介
(获取评级)
Ironwood PharmPharmticals,Inc.是一家保健公司,专注于胃肠(GI)产品的开发和商业化。它在美国和墨西哥以Linzess的名义销售利纳克肽,在加拿大和欧盟以Constella的名义销售利纳克肽,这是一种鸟苷环化酶C型激动剂,用于治疗患有便秘(IBS-C)或慢性特发性便秘(CIC)的成年人。
专题报道
- 免费获取StockNews.com关于铁木制药的研究报告(IRWD)
- 市场回顾周-1/23-1/27
- 为什么Lucid在一天内飙升了近100%
- 利用这些铁路股票实现增长和收入
- ASML预计今年芯片需求回升,提振销售观点
- KLA公司:在动荡不安的半市场中站稳脚跟
接受Ironwood PharmPharmticals Daily新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Ironwood PharmPharmticals和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧